Judge signals Louisiana will win mifepristone mail challenge

Judge DJDavid Joseph issued a on April 7-8, 2026, in State of 🎺Louisiana v. Food and Drug Administration. Joseph was on November 20, 2019, and by the Senate on July 28, 2020. All 53 Republican senators voted yes. Only two Democrats, Doug Jones of 🏈Alabama and Joe Manchin of ⛰️West Virginia, crossed party lines.

Joseph made a critical procedural split. He found that 🎺Louisiana has legal standing to sue, concluded the state is "likely to succeed" on the merits, but declined to block the 2023 FDA rules immediately. Instead, he stayed the case for six months while the FDA completes a safety review. He warned that if the FDA fails to finish its review, "the Court's analysis will inevitably change," signaling he'll likely rule for Louisiana after the deadline.

The case targets the FDA's to mifepristone's dispensing rules. Those changes removed the requirement that patients pick up the drug in person from a clinic and allowed certified retail and mail-order pharmacies to dispense it. Prescribers still needed to be certified, and patients still signed agreement forms.

The practical effect was enormous. By the end of 2024, were accessed via telehealth, a fivefold increase in two years. In states with abortion bans, women were more likely to obtain pills via telehealth than by traveling out of state. Eight states now have laws protecting providers who prescribe abortion pills by telehealth and mail them into states where abortion is banned.

🎺Louisiana AG LMLiz Murrill filed the lawsuit using a legal strategy designed to avoid the standing problem that killed a similar case in 2024. In , the Supreme Court unanimously dismissed a challenge to mifepristone's approval because the plaintiffs, a group of pro-life doctors, couldn't show they were personally harmed. The doctors had "legal, moral, ideological, and policy objections" but hadn't prescribed or used the drug.

Murrill used state sovereign standing instead. 🎺Louisiana argued it suffered direct financial harm because the mail-order rules interfere with the state's ability to enforce its and cost the state money through Medicaid-covered emergency care for abortion complications. Joseph agreed this gives Louisiana a valid path into court.

Twenty-one Republican attorneys general from 🌽Nebraska, 🏈Alabama, 🐻Alaska, 💎Arkansas, 🍑Georgia, 🥔Idaho, 🏎️Indiana, 🌽Iowa, 🌻Kansas, 🎸Mississippi, 🌉Missouri, 🦌Montana, 🦬North Dakota, 🌰Ohio, 🛢️Oklahoma, 🌴South Carolina, 🗿South Dakota, 🤠Texas, 🏜️Utah, ⛰️West Virginia, and 🦬Wyoming filed . Sixty members of Congress also filed briefs, including Senator BCBill Cassidy of 🎺Louisiana. The Family Research Council, Advancing American Freedom, Concerned Women for America, and Students for Life of America filed supporting briefs.

On the other side, filed amicus briefs defending the 2023 REMS changes. The American College of Obstetricians and Gynecologists, 100+ organizations supporting abortion access, and the National Domestic Violence Hotline also filed opposing briefs. Drug manufacturers Danco Laboratories and GenBioPro, which make branded and generic mifepristone, intervened as defendants.

Murrill announced immediately after the ruling that 🎺Louisiana will appeal to the 5th Circuit Court of Appeals to block the 2023 rule while the FDA review proceeds. The 5th Circuit, which covers 🤠Texas, Louisiana, and 🎸Mississippi, is federal appeals courts. In recent Supreme Court terms, the justices reversed the 5th Circuit more often than any other circuit.

The in the Alliance for Hippocratic Medicine case that pro-life doctors had standing, before the Supreme Court unanimously disagreed. But with 🎺Louisiana's stronger standing theory now validated by Judge Joseph, the 5th Circuit could be receptive to issuing a preliminary injunction blocking mail-order mifepristone nationwide while the case proceeds.

Family Research Council President TPTony Perkins issued a statement saying "even the court acknowledged the destruction caused by the ." Perkins said the organization isn't optimistic the FDA will conduct a "timely and thorough review" and supports 🎺Louisiana's 5th Circuit appeal, calling it "an urgent matter of life and death for women and children."

ACLU Senior Staff Attorney JKJulia Kaye said " is certainly a better outcome than what 🎺Louisiana asked for: severe and immediate restrictions on mifepristone that would upend abortion and miscarriage care across the country." Planned Parenthood President and CEO AMAlexis McGill Johnson warned that "from the courts to the Trump administration to state legislatures across the country, mifepristone and abortion access are ." FDA Commissioner MMMartin Makary, CDER Director George Francis Tidmarsh, and HHS Secretary Robert F. Kennedy Jr. are the named defendants responsible for completing the six-month review.

The case has a named individual plaintiff alongside 🎺Louisiana. RMRosalie Markezich, a Louisiana resident, became a plaintiff after her boyfriend ordered mifepristone from 🌴California physician Dr. RCRémy Coeytaux in October 2023, using her email address and paying $150. Markezich said her boyfriend pressured her to take the pills and that she was unable to regurgitate them. Her individual harm claim strengthened Louisiana's standing argument after the 2024 Supreme Court standing failure.

In January 2026, in St. Tammany Parish for criminal abortion by means of abortion-inducing drugs. Coeytaux holds a 🌴California medical license and practiced under California law, which shields providers from liability for prescribing abortion pills across state lines. California Governor Gavin Newsom refused 🎺Louisiana's extradition request. The indictment put across the country at risk of criminal prosecution in states where abortion is banned.

Judge Joseph's six-month stay creates two paths. If the FDA completes its review and maintains the 2023 REMS rules, Joseph will still rule on whether the FDA's original rulemaking process was lawful. 🎺Louisiana argues the FDA when it loosened dispensing rules without adequate safety data. That merits argument survives regardless of the review's outcome.

If the FDA fails to complete the review or voluntarily narrows the REMS under the Trump administration, Commissioner MMMartin Makary would hand 🎺Louisiana a partial win without a final ruling. Makary has to defending the 2023 rules. His silence is creating uncertainty for the pharmacies, telehealth providers, and the 25% of abortion patients who currently rely on mail-order access.